Index Performance
Overview
Description
Developed by Lux Capital, the Lux Bio + Tech Index™ is a secular investment theme that covers companies innovating to further the molecular understanding of the "omics stack" to companies building "operating systems" for the future of drug discovery and ultimately even drug development. Over time these companies have transformed from radical, even heretical, ideas to undeniable technical, scientific, and clinical proof points. The last decade has ushered in an unparalleled understanding of the molecular basis of biology, enabled by emergent tool kits to engineer and perturb biology, ultimately increasing the velocity of discovery. Today, Moore's Law-like cost curves exist along many axes in biotech and have given rise to an era of precise, high fidelity, large scale, highly reproducible, and increasingly automated biological and chemical experimentation and discovery. The modern scientist-entrepreneur not only sits at the wetbench but also has proficiency to deconvolute high dimensional and historically unmanageable data with GPUs, the cloud, and the array of advances from machine learning and deep learning.
Full methodology- TickerLUXBT
- Inception Date04/23/2021
- WeightingCustom
- # of holdings54
What's inside?
Holdings
All holdings as of September 27, 2023
BridgeBio Pharma, Inc. (BBIO) | 8.32% | $4.319B | -97.77% | -17.98% | 723.08x |
Schrödinger, Inc. (SDGR) | 3.61% | $1.721B | -8.53% | 39.25% | 17.10x |
Tango Therapeutics, Inc. (TNGX) | 3.56% | $1.126B | 152.95% | 89.67% | 0.64x |
Recursion Pharmaceuticals, Inc. (RXRX) | 3.25% | $1.545B | 43.56% | 0.32% | 22.97x |
Nuvalent, Inc. (NUVL) | 3.23% | $2.171B | N/A | N/A | N/A |
Third Harmonic Bio, Inc. (THRD) | 3.23% | $0.252B | N/A | N/A | N/A |
10X Genomics, Inc. (TXG) | 2.94% | $4.223B | 28.10% | 61.08% | 10.95x |
Evotec SE (EVO) | 2.83% | N/A | 1.12% | 27.20% | 4.94x |
Alector, Inc. (ALEC) | 2.60% | $0.539B | -29.60% | 96.03% | -0.85x |
Ionis Pharmaceuticals, Inc. (IONS) | 2.57% | $6.633B | 40.82% | 95.63% | 8.71x |
Sana Biotechnology, Inc. (SANA) | 2.43% | $0.742B | N/A | N/A | N/A |
ProKidney Corp. (DNAC) | 2.41% | $0.266B | N/A | N/A | N/A |
Roivant Sciences Ltd. (ROIV) | 2.35% | $9.577B | 400.67% | 56.98% | 90.73x |
Regeneron Pharmaceuticals, Inc. (REGN) | 2.25% | $88.852B | 10.53% | 83.91% | 5.97x |
Verve Therapeutics, Inc. (VERV) | 2.25% | $0.828B | N/A | -44.58% | 142.89x |
Janux Therapeutics, Inc. (JANX) | 2.20% | $0.459B | -55.31% | 55.44% | 28.15x |
Certara, Inc. (CERT) | 2.13% | $2.221B | 9.29% | 47.85% | 8.43x |
CRISPR Therapeutics AG (CRSP) | 2.12% | $3.662B | 44,203.80% | 29.15% | 17.15x |
ATAI Life Sciences NV (ATAI) | 2.10% | $0.211B | 1.18% | -13.37% | 222.37x |
Denali Therapeutics, Inc. (DNLI) | 2.02% | $2.939B | 460.45% | 99.54% | 8.81x |
Nuvation Bio, Inc. (NUVB) | 2.01% | $0.304B | N/A | N/A | N/A |
Nurix Therapeutics, Inc. (NRIX) | 1.98% | $0.411B | 168.33% | 89.13% | 4.55x |
Exscientia Plc (EXAI) | 1.92% | $0.575B | -57.96% | -230.07% | 9.47x |
Ginkgo Bioworks Holdings, Inc. (DNA) | 1.92% | $2.770B | -44.29% | 55.63% | 8.83x |
Intellia Therapeutics, Inc. (NTLA) | 1.90% | $2.863B | -3.11% | 84.04% | 52.99x |
Compass Pathways Plc (CMPS) | 1.83% | $0.483B | N/A | N/A | N/A |
Caribou Biosciences, Inc. (CRBU) | 1.83% | $0.433B | -10.42% | 70.01% | 2.04x |
Editas Medicine, Inc. (EDIT) | 1.77% | $0.576B | -54.62% | 46.66% | 9.97x |
Dyne Therapeutics, Inc. (DYN) | 1.76% | $0.550B | N/A | N/A | N/A |
SomaLogic, Inc. (SLGC) | 1.21% | $0.440B | 44.71% | 45.40% | -0.40x |
Nkarta, Inc. (NKTX) | 1.19% | $0.082B | N/A | N/A | N/A |
EQRx, Inc. (EQRX) | 1.11% | $1.077B | N/A | N/A | N/A |
SAGE Therapeutics, Inc. (SAGE) | 1.11% | $1.248B | 64.82% | 78.33% | 175.13x |
Olink Holding AB (OLK) | 1.08% | $1.806B | 6.93% | 58.74% | 14.97x |
Beam Therapeutics, Inc. (BEAM) | 1.07% | $1.869B | 20.80% | 63.76% | 19.23x |
Adaptive Biotechnologies Corp. (ADPT) | 1.06% | $0.804B | 12.06% | 51.84% | 4.13x |
Moderna, Inc. (MRNA) | 1.04% | $37.344B | -92.71% | -138.66% | 3.70x |
Ultragenyx Pharmaceutical, Inc. (RARE) | 1.01% | $2.674B | 21.23% | 90.85% | 9.05x |
Alnylam Pharmaceuticals, Inc. (ALNY) | 0.99% | $21.881B | 41.78% | 73.22% | 19.61x |
AbCellera Biologics, Inc. (ABCL) | 0.98% | $1.360B | -78.10% | 27.84% | 7.78x |
Lyell Immunopharma, Inc. (LYEL) | 0.97% | $0.387B | -99.92% | -16,711.11% | 5.49x |
Century Therapeutics, Inc. (IPSC) | 0.96% | $0.121B | -92.91% | -2,333.33% | 15.96x |
BioNTech SE (BNTX) | 0.96% | $24.754B | -94.63% | 2.86% | 1.13x |
Relay Therapeutics, Inc. (RLAY) | 0.95% | $1.016B | -67.40% | -1,021.01% | 756.31x |
Seer, Inc. (California) (SEER) | 0.95% | $0.134B | 10.69% | 23.03% | -1.17x |
Fate Therapeutics, Inc. (FATE) | 0.95% | $0.199B | -94.97% | -378.67% | 1.65x |
Vir Biotechnology, Inc. (VIR) | 0.94% | $1.242B | N/A | -84.30% | 3.18x |
Prime Medicine, Inc. (PRME) | 0.94% | $0.997B | N/A | N/A | N/A |
Erasca, Inc. (ERAS) | 0.93% | $0.320B | N/A | N/A | N/A |
4D Molecular Therapeutics, Inc. (FDMT) | 0.93% | $0.553B | 47.53% | -497.49% | 174.26x |
Kymera Therapeutics, Inc. (KYMR) | 0.87% | $0.849B | 43.42% | 94.55% | 20.29x |
Seres Therapeutics, Inc. (MCRB) | 0.83% | $0.299B | 10,300.74% | 97.07% | 4.64x |
Arvinas, Inc. (ARVN) | 0.83% | $1.116B | 74.12% | 97.06% | 1.84x |
Stoke Therapeutics, Inc. (STOK) | 0.82% | $0.172B | -176.79% | N/A | 27.38x |